HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
NUWE
Nuwellis, Inc.
There isn't enough reported data to score NUWE yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
NUWE Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Weak | |
| Weak | |
| Unavailable |
NUWE's revenue is currently stable, but its profitability and cash flow are weak. There isn't enough data to rate its balance sheet.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
NUWE PE Valuation
NUWE has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
NUWE Forward outlook
There aren't enough analyst estimates for NUWE to show an outlook.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
NUWE Earnings Per Share
NUWE and HIMS do not have enough comparable growth data to identify a winner.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over NUWE on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over NUWE on profitability, with a higher operating margin.
NUWE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $2.2M | -0.2% |
| Q2 2026 | $2M | +14% |
| Q1 2026 | $2.4M | +26% |
| Q4 2025 | $2.4M | +4.4% |
| Q3 2025 | $2.2M | -6.3% |
| Q2 2025 | $1.7M | -21% |
| Q1 2025 | $1.9M | +2.5% |
| Q4 2024 | $2.3M | -9% |
NUWE's revenue is growing: $2M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -93% | +29 points |
| Q2 2026 | -161% | +7.5 points |
| Q1 2026 | -190% | -29 points |
| Q4 2025 | -101% | +2 points |
| Q3 2025 | -122% | -57 points |
| Q2 2025 | -168% | -63 points |
| Q1 2025 | -161% | +95 points |
| Q4 2024 | -103% | +38 points |
NUWE's operating margin was −93% last quarter, up 29 points from the same quarter a year ago, near the top of its range since 2019.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over NUWE on cash generation, producing positive trailing cash flow while its opponent burns cash.
NUWE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$3M | +$282K |
| Q2 2026 | -$3.2M | -$1.1M |
| Q1 2026 | -$3.1M | -$606K |
| Q4 2025 | -$3M | -$1.5M |
| Q3 2025 | -$3.2M | -$790K |
| Q2 2025 | -$2.1M | +$677K |
| Q1 2025 | -$2.5M | +$355K |
| Q4 2024 | -$1.5M | +$1.2M |
NUWE has burned cash in almost every quarter: −$12M over the past year, against −$9M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over NUWE on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
NUWE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +206% | +13.6K shares |
| 1 year | +2984% | +19.5K shares |
| 3 years | +671167% | +20.1K shares |
NUWE has 20,138 diluted shares, up 2984% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
NUWE Net Leverage
NUWE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
NUWE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 25.7 | Oversold |
| Stochastic | 12.8 | Oversold |
NUWE's weekly RSI is 26 (oversold) and its Stochastic is 13 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
NUWE PE vs Healthcare Sector
NUWE has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
NUWE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $5.32 | 5.5% below |
| 20 week MA | $11.2 | 55% below |
| 50 week MA | $277.8 | 98% below |
| 100 week MA | $4,134.8 | 100% below |
| 200 week MA | $387,796.3 | 100% below |
NUWE is in a downtrend: it's below all five of its weekly moving averages, and 100% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over NUWE on returns for 2026, with the stronger performance.
NUWE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1,168,052,886.0 | $339,415,650.0 | -71% |
| 2021 | $339,415,650.0 | $56,955,150.0 | -83% |
| 2022 | $56,955,150.0 | $3,519,180.0 | -94% |
| 2023 | $3,519,180.0 | $268,985.8 | -92% |
| 2024 | $268,985.8 | $15,479.1 | -94% |
| 2025 | $15,479.1 | $642.6 | -96% |
| 2026 YTD | $642.6 | $5.03 | -99% |
NUWE has finished every year since 2020 lower, and it's down 99% so far in 2026.